Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Anti-PD-1 Antibodies / PD-1 Inhibitors & Esophageal squamous cell carcinoma (ESCC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Anti-PD-1 Antibodies / PD-1 Inhibitors are key in treating advanced Esophageal squamous cell carcinoma (ESCC). They are used with platinum/fluoropyrimidine chemotherapy as a first option. They are also used alone after other chemotherapy. They work best in PD-L1–positive cases. Guidelines and rules differ based on PD-L1 tests and levels.
Ma et al. 2023 Front Oncol 13: 1005856
Vilbert et al. 2024 J Clin Oncol 42: 366-366

see also:
Esophageal squamous cell carcinoma (ESCC) & Drugs/Treatments
[Immune Checkpoint Inhibitors (I…

References (Sources)

Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer
Ma et al. 2023 Front Oncol 13: 1005856
Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma
Vilbert et al. 2024 J Clin Oncol 42: 366-366

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Anti-PD-1 Antibodies / PD-1 Inhibitors & Esophageal squamous cell carcinoma (ESCC)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat